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Abstract A cDNA clone encoding a novel epidermal growth 
factor (EGF)-related growth regulator, epiregulin, was isolated 
from a cDNA library prepared from a mouse fibroblast-derived 
tumor cell line, NIH3T3/clone T7. The predicted amino acid 
sequence revealed that the purified epiregulin peptide of 46-amino 
acids was synthesized as an internal segment of a 162-amino acid 
putative transmembrane precursor. The structural organization 
was similar to that of TGF-a precursor among the members of 
the EGF family. Although epiregulin transcript was not detected 
in several adult normal tissues by Northern blot analysis, approx- 
imately 4.8-kb transcript was present in 7-day-old mouse embryo 
and then diminished to very low or undetectable levels. Our re- 
sults suggest hat epiregulin may play an important role in the 
regulation of epithelial cell growth during early development. 
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1. Introduction 
Peptide growth factors are involved in various physiological 
processes including embryogenesis, immune and inflammatory 
responses, oncogenic transformation, neuronal survival, and 
hematopoiesis. They bind to specific membrane receptors to 
trigger a cascade of intracellular signals, resulting in specific 
cellular responses [1,2]. The elucidation of the mechanisms of 
l igand-receptor interactions, signaling pathways, and activa- 
tion of transcriptional factors is useful for the understanding 
of the physiological role of these factors. 
We have recently purified a novel epidermal growth factor 
(EGF)-related growth regulator, epiregulin, from a mouse fi- 
broblast-derived tumor cell line, NIH3T3/clone T7 [3]. Epireg- 
ulin, along with EGF  and transforming rowth factor-~ (TGF- 
~), is a small polypeptide of 46-amino acid residues that belongs 
to the EGF family. It inhibits the growth of several epithelial 
tumor cell lines but stimulates various types of other cells. The 
binding of epiregulin to the EGF receptors on epidermoid car- 
cinoma A431 cells is weaker than that of EGF  [3]. Nevertheless, 
it is more potent than EGF as a mitogen for rat primary hepa- 
tocytes and Balb/c 3T3 A31 fibroblasts [3]. 
In the present study, we report the isolation and the nucleo- 
tide sequence of cDNA encoding mouse epiregulin. We ana- 
lyzed the expression of the epiregulin gene in several normal 
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Abbreviations: EGF. epidermal growth factor; TGF-~, transforming 
growth factor- ~; PCR, polymerase chain reaction; HB-EGF, heparin 
binding EGF-like growth factor. 
adult tissues and found that the expression was detected in the 
early stage of embryonic life, suggesting that the physiological 
significance of epiregulin is distinct from other members of the 
EGF family and that it is involved in the early development 
process as an EGF-related ligand. 
2. Materials and methods 
2~ 1. Amplification of epiregulin cDNA ji'agments for probes by PCR 
Poly (A) + RNA of NIH3T3/clone T7 cells was prepared with Fast 
Tract (Invitrogen, San Diego, CA) and oligo dT primed cDNA was 
synthesized using cDNA synthesis kit (Pharmacia, Uppsala, Sweden) 
according to the instructions provided by the manufacture. A cDNA 
library was constructed inAgt 10 (Stratagene, La Jolla, CA) as a vector. 
The following degenerated oligonucleotides were designed from the 
amino acid sequence of epiregulin and synthesized with an automated 
DNA synthesizer (Model 380B, Perkin-Elmer Instrument, Normalk, 
CT). P1, 5'-GTNCARATHACNAARTG-3'; P2, 5'-ARRAARAAR- 
TGYTCRCA-3'; P3, 5'-GTRTANCCNACYTCRCA-3' (N = A, T, G, 
C: R -- A, G; H = A, C, T; Y = C, T). P1 is a 5'-primer corresponding 
to amino acid residues 1-5, P2 and P3 are 3'-primers corresponding to
46~1, and 37-32, respectively (Fig. 1). 
PCR was performed using GeneAmp PCR reagent kit with Ampli- 
Taq DNA polymerase (Perkin-Elmer). Ten microliters of the phage 
suspension were boiled for 10 min and subjected to the first round PCR 
using PI and P2 as primers under the following conditions for 30 cycles: 
94°C for I rain, 40°C for 2 min, and 72°C for 3 min. Ten microliters 
of the first round PCR product were then applied to a second round 
PCR using PI and P3 as primers under the same conditions, and the 
nucleotide sequence of the PCR product (PR1) was determined as 
described below. P4 (5'-TAGTTCTGACATGGACGGCT-3'), P5 (5'- 
TGGACATGAGAGAGAAATTC-3'), P6 (5'-GAATTTCTCTCTC- 
ATGTCCA-3'), and P7 (5'-AGCCGTCCATGTCAGAACTA-3') were 
designed on the basis of the nucleotide sequence of PR1. GF (5'- 
AGCAAGTTCAGCCTGGTTAA-3') and GR (5'-ATGAGTATTTC- 
77CCAGGG-Y) are consensus to the sequence surrounding the EcoRI 
site of 2gtl0 and used as primers to amplify the suffers. Two more sets 
of nested PCR reactions were performed using the above primers as 
shown in Fig. 1. The annealing temperature was at 52°C for the first 
round PCR, while it was raised to 55°C for the second round PCR. 
The resulting products (PR2 and PR3) were subcloned into the SmaI 
I 
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Fig. 1. Strategy for the amplification of epiregulin cDNA fragments by 
PCR. Right and left directed arrows indicate 5'- and 3'-primers, respec- 
tively. The sequences ofoligonucleotide primers are described in section 
2. The stippled box indicate the region of the amino acid sequence 
determined from purified epiregulin. 
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1 AGCTCACTTGCCTGGCTGCTCAGAGTCACAGCGACTTGGTC-GGcTCTGGTACCTGGATCAGCTCGGTTCCAACTcAGCCAcAGGCACCTT 
91 GCTCCCGC GGCC GCCGCGCACTC  GCAAGCTGCACC GAGAAAGAAGGATGGAGACGCTCCCTGCCTC~rGGGTCTTGACGCTGC~TGT 
1 M E T L P A S W V L T L L C 
181 CTAGGTTC CCACCTTCTACAGGCAGTTATCAGCACAACC GTGATCCCATCATGCATCCCAGGAGAATCCGAGGATAACTGTACCGCCTTA 
15 L G S H L L Q A V I S T T V I P S C I P G E S E D N C T A L 
1 
451 CAAC C C TTGAGCAAAGAATAC GTTGC G~FrGACAGTGA~CTCATTTTCC TGT~I~C TCATCATAACC GC TGGATGC ATATACTATTTCTGC 
105 Q P L S K E Y V A L T V I L I, F L F L I I T ,A G C I Y Y F C 
541 AGATGGTACAAAAATCGAAAAAGTAAAAAATC GAGGGAGGAATATGAGAGAGTGAC C TCAGGGGAC CAGTGCTGC ACAGGTCTGAACA 
135 R W Y K N R K S K K S R E E Y E R V T S G D P V L P Q V --- 
631 GTGC CATC AAGTTAC GGACAAGGATTC ACAGTGTGC TGGCTGATGTCAATATI~TTC TCATGTTAATAATATTTATGTTGGGTCATCTGT 
721 TAGGTCAATAAcTATA~.~.1~.~AATACAATTGGAAAGTGz.~.z.~ATTTTTGACAGAAATATATTTGCTAATATATTATATGTA~AATATTTA 
811 ATATCAAAAC~KAATTTGATA%'I'~'i~TGTAAGAATTTC CTGAGTAC GATGCTTTATTGAAAAGC TTCAAAGTTCATTAAGC TGATGCAGTGC 
901 TTAGAGAGAGCAATGTC C AATCTGTGGCTTGGGAGGTGTCTGCAAGTOACATTC C G GAGC TTAGTGATATGGTCAAGTC CATTGCATC 
991 AGTAATTTA -u'-'I'I'I-iCTTC TTCTGTCTOTGATAATTGACTTGAC TGAATTATGGCTTC.~C ACAGTGGTTGGc GAGCCTC GTAGTATAGT 
1081 C AAATCAATTGCATAAGTAATTrATTTTC TAC TTCTTATGTCTGTGATAATTGCTTTGACTTTATTATCAT~TATTAAACAGTAATAACA 
1171 ATGGGACTTAGAGGAGGTAAACATAACTTATGTGCCTCAAACCAGCTAGTCCTGGACAAGATGTcTCTTCAGTATCTCTGCTATTGGGTT 
1261 C AGATGTGTCTAGGGGAACAAAGAAAAATTCATTAACAAACATTAGCTGC T  CAC CTATGTAGAGTATATCATGTGAGGTTGTTGCTTTG 
1351 AATATCAATCAGAAAATC CACATCTGAAGACAAATTTGAACC  CATTFIAGAGTATTTATTTTTATAGGGAATTTACTGAAGGATTGTAG 
1441 CATTAAAGCAGAATC CAAATCAAAGTAATTGTATr/ ' ITAAAATACAGGAGGGCGGGC CTAAC CAGATC TTGAC TGATATGGAAACGTAC 
1531 TTTTGTATTTCATGCTCAAGAGGA'I-----. -~TTTTTGcT~-~-.-~TTGT~GTTTTGTTGTTGTTATTITGTTTGTTTAACATGGAGTCTGAC 
1621 TC TAGTC CAGACTGGCCTCAAGCTCATC.GTTAACTC TC TGCTATAAC CTC CTGGGTTACAGTCATAC ATTAC GGTGC C CAGATTCAAAA 
1711 TGGTITTTCT~Dc.~k~TTTGTITTGTTcTG.~-'.~.'.~.GTTTGTTTGTT~GTTTGTTTGTTITTGT~F~GTTTTGTG r~ ' , -~G~AC~T 
18 01 ACAcAGTTCAGACAACATCTTTTTACAGATTTTA•AGCTTCATTTAAAAAACATATATCCAAATGCAGGAAGCAAAGAAAATACAGGAAA 
18 91 AAATAAATCACAATCTATTTTTCCAAAGGGGAAACACATTTGAAAGCTTTTAAAATGTAGACTTCATTATCCATACCCATGGAAACTAAA 
19 81 GAGAAGC TC, C C C CATTTCTTCGTC C TTTOTTTGCCTTTGTGGAAAGACAGAAGC, C TGGCC TCCACTC TCAGCTTGCAGGTC TTC GTGAG 
2 0 71 TCACTGAGAGGATTCCAGGCAGCTATCTCGAGAGCCACTGCTAGAACACCTTTTCcTGGAGC•CTC•CcccACCAAATGCTcAACCTTAc-•T 
2161 GGAATCTCCCTGGAACACATACCAGGTcAGGGAGGGCCGATCCTTCCTCCACCT.~.~.~.'.CCTGGCATATGT~F~AAGGTAACAAAAAGATCA 
2 2 51 GGAGTTGCCTCTGGCcTCTAAAGTGcCAAGGGACCAATCATTGATGTTCCATGGAGCCAGTcATGGAAATCCCTGGAAGGTTCACACAGC 
2 3 41 TC TCATC CAAAGC C CTGGC CTTGCTATGAGGGAAAGATTGAATAAGCAGC GAACAAGGCATTCTGGTGC A TAACTTGTGC ACACAC CAG 
2 4 31 C TCCAGC CTTTGC AGAATGACAGCTC TTI~TTTCTGAAGTAAC AGCACAC ACACTCATGTTTAAAAGGACAAAGGGGAATGAAGGTCA 
2 5 21 GT•AGATCTAAAAAGTGTATITCTTTGCCATTTGATTTGGCTGAAGGACAGTCAGCATCCTGTGTGAGAACACATTTTGAAAGC CCAATG 
2 611 ACATCAACTGGGTAAAGGAAACAcTAACCTGTTTCCAGTGACCTTAGCGTCTCCAGACAAAGGTTTAAAGCTTTTCAAGAACTGGGcTAA 
2 7 01 AACTCATcCAG~.~u.ATCTACAGAAGcTGAAAAcAGGC~TTTTAGATATTAGTATATTGGTATATGATATGGTATGATGCTTATGGTCTGC 
2 7 91 TATGAGCATTCC~GCATACCACATAACTAGATGCAAGAACCTTGGGGTAGCATTCTGTAT.~.~.~.~.AAATATGTTTTAAAAGAACTCAGG 
2881 AACAATTTACGTC TCTGTATC i'-'i'I'~', "I'~'xACTATTGTTGTTTTGACC TCAAA~C TGGGAATAAAAGTCAGAGC C TTACAC AT~TC C AGC 
2971 AAA CTATGGTTGGGATACACCTATTATCCCCTAAAAACATACAAATAATGCAAAAGGATGATGGAGCTTCCTGGTGTCGGGTGAACAT 
3061 GTT~ITAAAAAcTCATTGTTCTAGTGAAGATTATGTTAAGCAAGCCTAAAAAAA~ATGACAACCAGTTCATACACAGATTTCCCATTATAT 
3151 TGTGTATACAcACACAGGGACATCAAcAA•GGTAGTACACAcAcTATACT•AGAACCAAAGCAACCCCAGGTGCATAATTGTATAACTTA 
3241 CAGTCTCCCATCAAGACTAcCTCATAGTCCA~TAGATCCACTcCGTGACcAAC~GACATCATGCTCTGTATTTGACAGTAAAGTTTTACCT 
3331 TAAAAATGAGACTCCCAACTACCTAAAGCAC•cATCTTTGTAACTAGACCATAACTATACTGCTTTCATcTGGTTCACCcCCTCTATGTC 
3 4 21 AAGAGTC AAAC TGTGTGAGAAAAGc CAAAGATTI'FFFI~GAGTC C TTF/GAAGACAGC TAGC TAAATTTG CC TGC C AAAAGAT~T CAATT 
3 511 ATTGAATTGATACCTGTTTCTAGCAAATATATGACATGGcCTAGTGTCTTAA.~.~"~'.~TCCCACTccGTcAGTAATTTGA~AAGTTGCCT 
3 6 01 TTAAATCTTTTTAGTGAAC AAATTTGTC ACGTTTGGTTCAATTTTTTATTTTGTAGATi'TC.I-I-i-xAAAGTTTGATT~ATTTCC C GTTT 
3 6 91 TTTAAATC TTTTC TAATGTTCTGGGAAAC-G~GGAGC ATAAACAGCACTTTCAGGCTACATTTTAAAGTTCTAAC GGAAAAC TACATTTGT 
3 7 81 CTAAGATATCTC TGCTATTGACACATGATGCC TTTGAATGTCATAGAGCATA.,;~q-, .CTCTTTTTGC C TGTTT~CACTC TGC CATTGCACT 
3 8 71 TTGTAAATC TOTAGAATC GCTCGTATAAAATTTCTATTAAAGATTC AGTGAAACATAAAGTTGTATTGTGTTCAC CTTAAAACTTATTG 
3 9 61 ~ATTATGAATGTTATCAGAGTAC TGAATTGTATCAATTTGTTT~ CAGTTAATATC AGC TI"TGATAGTC AT GTAC C TTGAC ATAGT GAAG G 
4 0 51 ACACTATAATGTATGAGCTGTTGTCA~z'~'~'I'I'ATTTATTTTTTGTTAGGAATTGG 
Fig. 2. Nucleotide sequence and deduced amino acid sequence of mouse piregulin cDNA. (A) Nucleotide and deduced amino acid sequence. The 
boxed sequence indicates mature piregulin. The bold underline indicates the putative transmembrane segment. A destabilizing signal (TTATTTATT) 
for cyotokine and proto-oncogene mRNA is underscored with a single line. The potential N-glycosylation site is denoted by an asterisk. Numbers 
on the left indicate nucleotide (above) and amino acid positions (bottom). 
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Fig. 2. (B) Hydropathy profile of the deduced amino acid sequence based on the algorithm of Kyte and Doolittle [26], The nucleotide sequence will 
appear in the DDBJ/ENBL/GeneBank sequence data bank under the accession umber D30782. 
site of pUCI8, and sequenced to confirm that each fragment encoded 
a part of epiregulin. 
2.2. Screening oJ the eDNA library 
Epiregulin cDNA fragments amplified by PCR (PR2 and PR3) were 
labeled with [~32p] dCTP using multiprime labeling kit (Amersham, 
UK). Filter hybridization was carried out at 68°C for 16 hours in a 
buffer containing 5 x SSC, 5 x Denhardt's olution, 0.5% SDS, 100 
mg/ml of sonicated heat-denatured salmon sperm DNA, and the ~zp, 
labeled probe. The blots were washed once in 2 × SSC for 30 rain at 
68°C, twice in 0.2 x SSC under the same conditions, and then Kodak 
X-Omat AR films were exposed to the filters at -70°C with intensifying 
screens. The clones containing the longest insert were isolated and the 
insert (mTG7a) was subcloned into the EcoRl site of pUCI8 for DNA 
sequencing. 
5'-terminal portion of the cDNA was amplified using RASE system 
(Gibco-BRL}. The 5'-terminal portion was synthesized using P6 as a 
primer and an oligo-dC anchor sequence was added to the 5'-end of 
cDNA by terminal deoxynucleotidy[ transferase, as the PCR template. 
The PCR reaction was performed at annealing temperature 55°C. P7 
and a commercially supplied anchor primer were used as PCR primers. 
Amplified cDNA fragment of 340-bp contained the overlapped regions 
with mTG7a. 
2.3. DNA sequencing 
The nucleotide sequence was determined by the dideoxynucleotide 
chain terminator method [4] using the Sequenase DNA-sequencing kit 
(United States Biochemical Co., Cleveland, OH). The longest eDNA 
insert, mTG7a, subcloned into pUC as partially digested with exonu- 
clease IlI from one end using Kilo-sequencing kit (Takara Sfiuzou, Co,. 
Kyoto, Japan), and the resultant deletion derivatives were sequenced. 
Both strands of the cDNA were completely sequenced atleast twice to 
confirm the sequence. At least three different clones from each PCR 
product were sequenced to determine the final consensus sequence. 
2.4. Northern bh)t analysis 
Mouse poly (A)- RNAs from several normal organs, mouse Multiple 
Tissue Northern (MTN) blot. and mouse mbryo MTN blot filters were 
purchased from Clontech Laboratories, Inc. (Palo Alto, CA). Poly (A) + 
RNAs were separated through 1% agarose gel containing formaldehyde 
and transferred onto nylon membranes (Hybond N; Amersham}. 
Northern blot hybridization was carried out using 763-bp Hhal Hin- 
dill fragment of epiregulin eDNA as a probe which contained the open 
reading frame, under high stringent conditions recommended by the 
manufacture of the MTN blots. Two MTN blots of different lot num- 
ber in each experiment were used for Northern blot hybridization. 
3. Results and discussion 
3.1. Isolation o]" eDNA encoding epiregulin 
Fig. I illustrates the strategy used to amplify several parts of 
epiregulin cDNA by PCR as described above. The amino acid 
sequence predicted from the nucleotide sequence of PR1 (110 
bp) was identical to that of epiregulin corresponding to amino 
acid residues 1 37. Comparison of the nucleotide sequences of 
PR2 (401 bp) and PR3 (310 bp) with that of PR1 showed that 
PR 1 contained regions that overlapped with PR2 and PR3. By 
screening N1H3T3/clone T7 cDNA library using both PR2 and 
PR3 as probes, 14 positive clones were isolated from approxi- 
mately 3.5 x 105 pharges. Among these, three clones contained 
an insert of approximately 4.1 kb, that gave bands of similar 
size upon cleavage with Pstl and Accl, suggesting that they had 
the same reaction enzyme sites. The nucleotide sequence of one 
of these clones was determined. It appeared that the clone had 
covered nucleotides 434,105. Since the length of epiregulin 
transcript was estimated to be about 4.8 kb (Fig. 4), we cloned 
the proximal and the distal 5'-end of the cDNA using a similar 
nested PCR nucleotide and determined the nucleotide se- 
quences 1 42. 
3.2. Structure analysis of  eDNA encoding epiregulin 
Fig. 2A shows the nucleotide sequence of a 4,105 bp eDNA 
and the deduced amino acid sequence. The cDNA encoded 
single open reading frame for a protein of 162 amino acid 
residues flanked by a 140 bp 5'-untranslated region and a 3,476 
bp 3'-untranslated region. Since the open reading frame con- 
tained the entire epiregulin sequence, it is likely that the protein 
is the precursor of epiregulin. Though the first ATG was not 
preceded by the optimal consensus equence for translational 
initiation sites [5], it was thought to be a start site due to the 
406 
similarity of amino acid sequence to that of human homologue 
(H. Toyoda et al., unpublished ata). The Y-untranslated re- 
gion was rich in A/T repeats and contained a destabilizing 
signals (TTATTTATT) for cytokines and proto-oncogene 
mRNAs [6,7], suggesting that epiregulin mRNA undergoes 
rapid turnover. Since this cDNA had no poly (A) + tail, it ap- 
peared to lack about 700 bp from the untranslated region. 
Hydropathy analysis revealed that the first ATG was followed 
by a hydrophobic region, which seemed to be the signal peptide 
(Fig. 2B). Although the precise processing site of the signal 
peptide was unclear, based on the criteria of von Heijne [8,9], 
amino acid residues 1-22 was most likely the signal peptide. In 
addition, a highly hydrophobic stretch was observed at residues 
113-132, which was considered to be a putative transmembrane 
domain. A potential N-linked glycosylation site was found in 
the amino-terminal region of the epiregulin precursor at residue 
40. These features are characteristic of the genes of proteins 
belonging to the EGF family, including EGF [10,11], TGF-7 
[12,13], amphiregulin [14], heparin-binding EGF-like growth 
factor (HB-EGF) [15], and betacellulin [16] (Fig. 3). The mature 
forms of amphiregulin, HB-EGF, and betacellulin carry rela- 
tively long N-terminal regions followed by EGF-like domains, 
whereas epiregulin as well as EGF and TGF-~ do not. Among 
EGF family members, however, the length of not only the 
mature form but the pro-region, which precedes mature pro- 
tein, varies considerably. For instance, mature TGF-~ of 50 
residues is flanked by the pro-region of 17 to 18 residues. The 
pro-domain of EGF spans 950 residues and contains mature 
form of 53 residues and nine EGF-like sequences. On the other 
hand, the length of mature amphiregulin and its pro-region are 
84 and 81 residues, respectively. In the case of epiregulin, the 
mature and pro-region forms were 46 and 33 residues, respec- 
tively. In this respect, the structure of epiregulin precursor is 
very similar to that of TGF-~. 
The purified epiregulin was an internal segment of the pre- 
cursor. The members of the EGF family are all released as 
soluble forms by proteolytic processing from the ectodomain 
of their transmembrane precursors. It is likely that the mature 
epiregulin is cleaved out from the precursor. The cleavage of 
mature TGF-~ of 50-amino acids from the precursor occurs 
between alanine and valine residues at both N- and C-termini 
[12,13]. The precursor form of epiregulin does not carry such 
EGF-hke domain 
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Fig. 3. Schematic representations of structural comparison of EGF-like 
growth factor precursors. The predicted structural organizations of 
their precursors are indicated as follows: signal peptide (stippled boxl, 
mature peptide (blacked box), and the transmembrane domain (cross- 
hatched box). 
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Fig. 4. Northern blot analysis of mouse epiregulin mRNA. Nylon 
membranes filters, onto which 2 pg of poly (A) + RNAs were trans- 
ferred, were probed with 763-bp HhaI-HindIII fragment of epiregulin 
cDNA or fl-actin. Mouse MTN blot filters were used in (B) and (C). 
(A) NIH3T3/clone T7. (B) Normal adult tissues, lane 1, heart; lane 2, 
brain; lane 3, spleen; lane 4, lung; lane 5, liver; lane 6, skeletal muscle; 
lane 7, kidney; lane 8, testis. (C) Early embryos, lane 1, 7-day-old; lane 
2, 1 l-day-old; lane 3, 15-day-old; lane 4, 17-day°old mouse embryos. 
The 7-day-old and 11-day-old embryos include the extra-embryonic 
membranes. The 15-day-old and 17-day-old embryos do not. The arrow 
head indicates the position of an approximately 4.8 kb epiregulin tran- 
script. 
sequences. Mature form of epiregulin, as well as those of am- 
phiregulin [14,17], HB-EGF [15, 18], and betacellulin [16], are 
processed at different sequences of N- and C-termini. There are 
no consensus cleavage sites for the proteinase in the precursors 
of proteins that belong to the EGF family. Therefore, distinct 
proteinases or a proteinase with a broad specificity may process 
the precursor. 
3.3. EYpression of epiregulin mRNA 
Northern blot analysis howed that an epiregulin transcript 
of approximately 4.8-kb was expressed at high levels in 
NIH3T3/clone T7 cells (Fig. 4A), while it was not detected in 
normal tissues of adult mice including the liver, lung, kidney, 
heart, brain, spleen, testis, smooth and skeletal muscles (Fig. 
4B). This is in contrast o other members of the EGF family 
that are expressed ubiquitously in a variety of normal organs. 
This finding indicates that the expression profile of epiregulin 
is distinct from other members of the EGF family. 
The expression of epiregulin during development of the 
mouse whole embryo is demonstrated in Fig. 4C. The expres- 
sion of epiregulin was limited to 7-day-old embryo, and was 
very low or undetectable in 9- to 17-day-old embryos. Similar 
expression profiles during fetal development have been re- 
ported in those of TGF-c~ [19-22]. The highest expressions of 
mouse and rat TGF-c~ are observed on day 7 to 9 [19] and on 
day 8 to 9 [20], respectively, but diminish after that to undetect- 
able levels. 
Recently, mice homozygous for a disrupted EGF receptor 
gene have been generated [23 25]. The mutation resulted in 
peri-implantation, mid-gestational and postnatal mortality de- 
pending on the genetic background. Therefore, epiregulin may 
together with other EGF-related ligands play a role in the early 
stage of development. Further study for epiregulin localization 
14. Toyoda et al . /FEBS Letters 377 ,' 1995) 403 407 407 
in the early development process will give us its functional 
significance. 
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